ZURICH, Nov 24 (Reuters) - Novartis is initiating a previously announced share buyback worth up to $2.5 billion, it said here on Tuesday as it highlighted its research and development pipeline in an investor presentation.

It also increased its target for a technical operations productivity programme starting in 2021 to $2 billion from $1.5 billion and said it was committed to driving constant margin expansion. (Reporting by Michael Shields; editing by Thomas Seythal)

Source: Reuters

Powered by NewsAPI.org